Notice to convene extraordinary GENERAL MEETING REGARDING EXTRAORDINARY DIVIDEND GUBRA A/S CVR NO. 30 51 40 41 To the shareholders of Gubra A/S (CVR no. 30 51 40 41), notice is hereby given to convene an extraordinary general meeting of…
Today, Gubra releases its results for the first quarter of 2025. The key development in the quarter was the out-licensing agreement to AbbVie for our anti-obesity asset GUBamy (Amylin). A landmark deal worth USD 2.2 billion in upfront and milestones…
A Transformative Quater for Gubra Today, we share our Q1 2025 results - a quarter marked by a transformative milestone: We’ve entered into an out-licensing agreement with AbbVie for our internally developed anti-obesity asset GUBamy. This landmark deal represents a…
Following Gubra’s Annual General Meeting 2025 taking place earlier today we are pleased to confirm some exciting changes to the Board welcoming new perspectives to support the journey ahead. As recommended by the Nomination Committee, the following members were re-elected…
On Thursday, 3 April 2025 at 10:00 am (CEST), the annual general meeting of Gubra A/S (the "Company") was held at the Company's registered address Hørsholm Kongevej 11B, DK-2970 Hørsholm, with the following agenda:1. The board of directors’ report on…
With reference to Gubra's A/S (CPSE: GUBRA) announcement on March 28, 2025 regarding the satisfaction of the regulatory condition for a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity, all closing conditions…
GUBamy was well tolerated with adverse events being predominantly GI related, mild and consistent with data from the SAD study. Doses of 1 mg and 2 mg GUBamy administered once-weekly for six weeks led to a dose dependent mean weight…
With reference to AbbVie's (NYSE: ABBV) and Gubra A/S' (CPSE: GUBRA) joint announcement of March 3, 2025 regarding a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity, the US Federal Trade Commission…
Notice to convene ANNUAL GENERAL MEETING 2025 GUBRA A/S CVR NO. 30 51 40 41 To the shareholders of Gubra A/S (CVR no. 30 51 40 41), notice is hereby given of the annual general meeting of Gubra A/S (the…
Partnership marks AbbVie’s entrance into the obesity fieldAgreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie’s global infrastructure for developing and commercializing therapies for patients in needAbbVie (NYSE: ABBV) and Gubra A/S…